<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04457752</url>
  </required_header>
  <id_info>
    <org_study_id>HITIDE</org_study_id>
    <nct_id>NCT04457752</nct_id>
  </id_info>
  <brief_title>Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®)</brief_title>
  <official_title>A Randomised Controlled Multicentre Clinical Trial, Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®) and Standard of Care Versus Standard of Care Alone in the Healing of Chronic Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SerenaGroup, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tides Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SerenaGroup, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized Controlled Multicenter Clinical Trial, Evaluating the Efficacy of Dual Layer&#xD;
      Amniotic Membrane (Artacent®) and Standard of Care versus Standard of Care alone in the&#xD;
      healing Chronic Diabetic Foot Ulcers. Multi-center, open label, randomized controlled trial.&#xD;
      Study is estimated to require 12 months from first subject enrolled to last subject visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic foot ulcers (DFUs) challenge the most experienced wound care specialist. The US&#xD;
      Wound Registry reports that only 40% of DFUs heal in 12 weeks1. Woundologists have adopted&#xD;
      the phrase, &quot;time is tissue.&quot; This adage reminds clinicians that the longer a DFU remains&#xD;
      open, the greater the risk of infection, major amputation and death. The diabetic with a foot&#xD;
      ulcer has a mortality rate of 47% which exceeds the mortality2 from most common cancers3.&#xD;
      Beyond patient suffering, the treatment of DFUs cost the US health care system more than 15&#xD;
      billion dollars annually4.&#xD;
&#xD;
      In recent years, several clinical trials have demonstrated that products derived from human&#xD;
      placental membranes promote the healing of DFUs5. Research has confirmed that growth factors&#xD;
      present in amniotic membrane induce angiogenesis, stimulate human dermal fibroblast&#xD;
      proliferation, and recruit stem cells important to wound repair and regeneration to the DFU6.&#xD;
      All these factors are highly desirable properties in the healing of chronic DFUs.&#xD;
&#xD;
      A novel dual layer amniotic membrane (DLAM, Artacent™, Tides Medical. Lafayette, LA)&#xD;
      potentially can increase the delivery of growth factors due to its double layer of amniotic&#xD;
      membrane. A prospective case series demonstrated good healing rates in DFUs: 65% healing at&#xD;
      12 weeks7. The current study is the first randomized clinical trial evaluating the efficacy&#xD;
      of DLAM in DFUs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Dual Layer Amniotic Membrane (DLAM). Artacent® Artacent® is a double layer of dehydrated amniotic membrane. The amnion is harvested from human placenta obtained during planned Caesarean sections. Tides Medical uses a proprietary process to clean and decellularize the amniotic membrane. The amnion is then folded into a bi-layer with the stromal sides facing outward. The dual layer is dried and cut into various sizes. In the final step the DLAM is terminally sterilized.&#xD;
Atracent®, like all other placental-derived products, is FDA cleared for homologous use through the 361 pathway. It is indicated for non-healing ulcers applied to a debrided, clean and uninfected ulcers.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Wound Closure</measure>
    <time_frame>1-12 weeks</time_frame>
    <description>- The percentage of target ulcers achieving complete wound closure in 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Wound Area Reduction</measure>
    <time_frame>1-12 weeks</time_frame>
    <description>- Percentage wound area reduction from TV-1 to TV-13 measured weekly with digital photographic planimetry and physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1-12 weeks</time_frame>
    <description>The number of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time wearing offloading boot</measure>
    <time_frame>1-12 Weeks</time_frame>
    <description>- Compliance with a prescribed offloading boot measured as % of time wearing the boot</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scale (The Pain, Enjoyment of Life and General Activity Scale). 0 = no pain , 10 = pain as bad as you can imagine</measure>
    <time_frame>TV-1, 3 weeks, 6 weeks, 9 weeks, and 12 weeks or Final Visit</time_frame>
    <description>- Change in pain in the target ulcer assessed using the PEG scale. [Time Frame: TV-1, 3 weeks, 6 weeks, 9 weeks, and 12 weeks or Final Visit]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in bacterial Load</measure>
    <time_frame>1-12 Weeks</time_frame>
    <description>- Exploratory Endpoint: changes in bacterial load measured using fluorescence imaging</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Chronic Diabetic Foot Ulcers</condition>
  <arm_group>
    <arm_group_label>Dual Layer Amniotic Membrane (DLAM) + SOC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DLAM (Up to 10 weekly DLAM applications) + Standard of Care (sharp debridement, offloading, and proper moisture balance).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care: sharp debridement, offloading, and proper moisture balance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dual Layer Amniotic Membrane (DLAM). Artacent®</intervention_name>
    <description>Artacent® is a double layer of dehydrated amniotic membrane. The amnion is harvested from human placenta obtained during planned Caesarean sections. Tides Medical uses a proprietary process to clean and decellularize the amniotic membrane. The amnion is then folded into a bi-layer with the stromal sides facing outward. The dual layer is dried and cut into various sizes. In the final step the DLAM is terminally sterilized.&#xD;
Atracent®, like all other placental-derived products, is FDA cleared for homologous use through the 361 pathway. It is indicated for non-healing ulcers applied to a debrided, clean and uninfected ulcers.</description>
    <arm_group_label>Dual Layer Amniotic Membrane (DLAM) + SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must be at least 18 years of age or older,&#xD;
&#xD;
          2. Subjects must have a diagnosis of type 1 or 2 Diabetes mellitus.&#xD;
&#xD;
          3. At randomization subjects must have a target ulcer with a minimum surface area of 0.7&#xD;
             cm2 and a maximum surface area of 20.0 cm2 measured post debridement with the Tissue&#xD;
             Analytics photographic planimetry App.&#xD;
&#xD;
          4. The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52&#xD;
             weeks of standard of care prior to the initial screening visit.&#xD;
&#xD;
          5. The target ulcer must be located on the foot with at least 50% of the ulcer below the&#xD;
             malleolus.&#xD;
&#xD;
          6. The target ulcer must be full thickness without exposed bone.&#xD;
&#xD;
          7. The affected limb must have adequate perfusion confirmed by vascular assessment. Any&#xD;
             of the following methods performed within 3 months of the first screening visit are&#xD;
             acceptable:&#xD;
&#xD;
               1. ABI between 0.7 and ≤ 1.3;&#xD;
&#xD;
               2. TBI ≥ 0.6;&#xD;
&#xD;
               3. TCOM ≥ 40 mmHg;&#xD;
&#xD;
               4. PVR: biphasic.&#xD;
&#xD;
          8. If the subject has two or more ulcers, they must be separated by at least 2 cm. The&#xD;
             largest ulcer satisfying the inclusion and exclusion criteria will be designated as&#xD;
             the target ulcer.&#xD;
&#xD;
          9. Target ulcers located on the plantar aspect of the foot must be offloaded for at least&#xD;
             30 days prior to randomization.&#xD;
&#xD;
         10. The subject must consent to using the prescribed off-loading method for the duration&#xD;
             of the study.&#xD;
&#xD;
         11. The subject must agree to attend the weekly study visits required by the protocol.&#xD;
&#xD;
         12. The subject must be willing and able to participate in the informed consent process.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A subject known to have a life expectancy of &lt; 6 months is excluded.&#xD;
&#xD;
          2. The subject is excluded if the target ulcer is not secondary to diabetes.&#xD;
&#xD;
          3. If the target ulcer is infected or if there is cellulitis in the surrounding skin, the&#xD;
             subject is excluded.&#xD;
&#xD;
          4. If there is evidence of osteomyelitis complicating the target ulcer, the subject is&#xD;
             excluded.&#xD;
&#xD;
          5. A potential subject cannot have an infection in the target ulcer or in a remote&#xD;
             location that requires systemic antibiotic therapy.&#xD;
&#xD;
          6. A subject receiving immunosuppressants (including systemic corticosteroids at doses&#xD;
             greater than 10 mg of Prednisone per day or equivalent) or cytotoxic chemotherapy is&#xD;
             excluded.&#xD;
&#xD;
          7. The topical application of steroids to the ulcer surface within one month of initial&#xD;
             screening is not permitted.&#xD;
&#xD;
          8. A subject with a previous partial amputation on the affected foot is excluded if the&#xD;
             resulting deformity impedes proper offloading of the target ulcer.&#xD;
&#xD;
          9. If a subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3&#xD;
             months of the initial screening visit he/she is excluded.&#xD;
&#xD;
         10. The subject is excluded if the surface area measurement of the Target ulcer decreases&#xD;
             by 40% or more during the 4-week screening phase: the 4 weeks from the initial&#xD;
             screening visit (SV1) to the TV-1/randomization visit during which time the subject&#xD;
             received SOC.&#xD;
&#xD;
         11. A Subject with an acute Charcot foot, or an inactive Charcot foot, that impedes proper&#xD;
             offloading of the target ulcer is excluded.&#xD;
&#xD;
         12. Women who are pregnant or considering becoming pregnant within the next 6 months are&#xD;
             excluded.&#xD;
&#xD;
         13. A potential subject with end stage renal disease requiring dialysis is excluded.&#xD;
&#xD;
         14. A subject who participated in a clinical trial involving treatment with an&#xD;
             investigational product within the previous 30 days is excluded.&#xD;
&#xD;
         15. A subject who in the opinion of the investigator, has a medical or psychological&#xD;
             condition that may interfere with study assessments is excluded.&#xD;
&#xD;
         16. A Subject treated with hyperbaric oxygen therapy or a Cellular and/or Tissue Product&#xD;
             (CTP) in the 30 days prior to the initial screening visit is excluded.&#xD;
&#xD;
         17. A Subject is excluded if the MolecuLight Device shows a positive fluorescence image in&#xD;
             the wound bed on TV1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas E Serena, MD,FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Serena Group, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas E Serena, MD,FACS</last_name>
    <phone>814-688-4000</phone>
    <email>serena@serenagroups.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Doug Payne</last_name>
    <phone>888-494-4441</phone>
    <email>dpayne@tidesmedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Titan Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwadjo Walker</last_name>
      <email>kwalker@viableresearch.org</email>
    </contact>
    <contact_backup>
      <last_name>Noreen Rana</last_name>
      <email>nrana.alas@viableresearch.org</email>
    </contact_backup>
    <investigator>
      <last_name>Yadwinder Dhillon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Hope Podiatry</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis Morfin</last_name>
      <email>francis_morfin@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Demitric Lopez</last_name>
      <email>demitriclopez@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Charles E Ananian, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Research</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yalily Perez</last_name>
      <email>yalilyp@royalresearchcorp.com</email>
    </contact>
    <contact_backup>
      <last_name>Yaili Perez</last_name>
      <email>yailip@royalresearchcorp.com</email>
    </contact_backup>
    <investigator>
      <last_name>Melissa Perlman, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pharma Research Associates</name>
      <address>
        <city>Westchester</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Regional Infectious Disease and Infusion Center, Inc</name>
      <address>
        <city>LaGrange</city>
        <state>Georgia</state>
        <zip>30240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bhuvan Doneepudi, MS</last_name>
      <email>bhuvan@nobadbugs.com</email>
    </contact>
    <investigator>
      <last_name>Ravi Kamepalli@nobadbugs.com</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hoosier Foot and Ankle</name>
      <address>
        <city>Fishers</city>
        <state>Indiana</state>
        <zip>46037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheri Britt</last_name>
      <email>cheribhfa@outlook.com</email>
    </contact>
    <contact_backup>
      <last_name>James Vestile, DPM</last_name>
      <email>jvestile@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>James Vestile, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Serena Group Baton Rouge</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas E Serena, MS, FACS</last_name>
      <email>serena@serenagroups.com</email>
    </contact>
    <contact_backup>
      <last_name>Khristina Serena</last_name>
      <email>kserena@serenagroups.com</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Serena, MD,FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Opelousas Medical Research Consultants, LLC</name>
      <address>
        <city>Opelousas</city>
        <state>Louisiana</state>
        <zip>70570</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerry Thibodeaux, MD</last_name>
      <email>KerryThibodeaux1960@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Marcus Speyrer</last_name>
      <email>mspeyrer@thewoundtreatmentcenter.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kerry Thibodeaux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai St. Luke's Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Alabi</last_name>
      <email>Denise.Alabi@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>John Lantis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Foot and Ankle Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Windy Cole, DPM</last_name>
      <email>drwec@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Stacey Coe</last_name>
      <email>scoe3@kent.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Windy Cole, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heal Foundation</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lam Le, MD</last_name>
      <email>lam.le@sjmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Phil Salon</last_name>
      <email>philbert.salon@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lam Le, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Foot and Ankle Wellness Center of Western Pennsylvania</name>
      <address>
        <city>Ford City</city>
        <state>Pennsylvania</state>
        <zip>16226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Schrecengost</last_name>
      <phone>724-664-3843</phone>
      <email>nschrecengost@serenagroups.com</email>
    </contact>
    <investigator>
      <last_name>Matthew Sabo, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Armstrong County Memorial Hospital - Wound Clinic</name>
      <address>
        <city>Kittanning</city>
        <state>Pennsylvania</state>
        <zip>16201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryan Doner, DO</last_name>
      <email>DrDoner@dandpmedicalgroup.com</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Schrecengost, LPN</last_name>
      <email>nschrecengost@serenagroups.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bryan Doner, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Martin Foot and Ankle</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Mincer</last_name>
      <email>beth@martinfootandankle.com</email>
    </contact>
    <investigator>
      <last_name>Maria Kasper, DMP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mt.Olympus Medical Research</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Management Group</name>
      <address>
        <city>Coto Laurel</city>
        <zip>00780</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>June 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

